keyword
MENU ▼
Read by QxMD icon Read
search

Bupropion

keyword
https://www.readbyqxmd.com/read/28203348/flibanserin-for-hypoactive-sexual-desire-disorder-place-in-therapy
#1
REVIEW
Faina Gelman, Jessica Atrio
The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access...
January 2017: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/28198465/fatigue-related-impairments-in-oculomotor-control-are-prevented-by-norepinephrine-dopamine-reuptake-inhibition
#2
Charlotte J W Connell, Benjamin Thompson, Jason Turuwhenua, Alexa Srzich, Nicholas Gant
Fatigue-induced reductions in saccade velocity have been reported following acute, prolonged exercise. Interestingly, the detrimental impact of fatigue on oculomotor control can be prevented by a moderate dose of caffeine. This effect may be related to central catecholamine upregulation via caffeine's action as an adenosine antagonist. To test this hypothesis, we compared the protective effect of caffeine on oculomotor control post-exercise to that of a norepinephrine-dopamine reuptake inhibitor. Within a placebo-controlled crossover design, 12 cyclists consumed placebo, caffeine or a norepinephrine-dopamine reuptake inhibitor (bupropion) during 180 minutes of stationary cycling...
February 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28187400/can-c-reactive-protein-inform-antidepressant-medication-selection-in-depressed-outpatients-findings-from-the-co-med-trial
#3
Manish K Jha, Abu Minhajuddin, Bharathi S Gadad, Tracy Greer, Bruce Grannemann, Abigail Soyombo, Taryn L Mayes, A John Rush, Madhukar H Trivedi
OBJECTIVE: Currently, no valid measures inform treatment selection for depressed patients. Whether C-reactive protein (CRP) in particular and two other acute phase reactants (inflammatory markers) could differentiate between patients responding to either of two treatments with different mechanisms of action was assessed. METHOD: Subjects included Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants randomly assigned to either escitalopram plus placebo (SSRI monotherapy, n=51) or bupropion plus escitalopram combination (bupropion-SSRI combination, n=55) with baseline plasma samples...
January 24, 2017: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/28181177/outcomes-associated-with-generic-drugs-approved-using-product-specific-determinations-of-therapeutic-equivalence
#4
Joshua J Gagne, Jennifer M Polinski, Wenlei Jiang, Sarah K Dutcher, Jing Xie, Joyce Lii, Lisa A Fulchino, Aaron S Kesselheim
OBJECTIVE: We sought to examine rates of clinical outcomes among patients before and after market introduction of generic versions of five drugs approved using product-specific equivalence determinations. METHODS: We used data from a large national insurer to identify patients who initiated a study (acarbose tablets, salmon calcitonin nasal spray, enoxaparin injection, vancomycin capsules, venlafaxine extended-release tablets) or control drug (nateglinide, glimepiride, alendronate, fondaparinux, metronidazole, sertraline, paroxetine) in each calendar month between 2003 and 2012 and to determine rates of claims-based proxies for lack of effectiveness outcomes following initiation...
February 8, 2017: Drugs
https://www.readbyqxmd.com/read/28167895/a-comparison-of-the-efficacy-of-varenicline-and-bupropion-and-an-evaluation-of-the-effect-of-the-medications-in-the-context-of-the-smoking-cessation-programme
#5
Ali Ramazan Benli, Selman Erturhan, Muhammet Ali Oruc, Pinar Kalpakci, Didem Sunay, Yeltekin Demirel
BACKGROUND: Within the context of the support program for smoking cessation, initiated by the Turkish Ministry of Health in 2011, those who present at 'smoking cessation' centres and are found to be suitable for pharmacological treatment are given varenicline and bupropion free of charge. As the smoking cessation programme is centralized, the selection of the medication is made randomly to provide a fixed distribution rate. The aim of this study was to evaluate the efficacy of both varenicline and bupropion in smoking cessation and to evaluate the effect of the smoking cessation programme...
2017: Tobacco Induced Diseases
https://www.readbyqxmd.com/read/28162685/-434-considerations-for-perioperative-contrave-naltrexone-hcl-bupropion-hcl-administration
#6
M Shehebar, Y Khelemsky
No abstract text is available yet for this article.
April 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/28150971/effects-of-bupropion-sustained-release-on-task-related-eeg-alpha-activity-in-smokers-individual-differences-in-drug-response
#7
Jian Zhu, Ryan P Coppens, Norka E Rabinovich, David G Gilbert
The mechanisms underlying bupropion's efficacy as an antidepressant and a smoking cessation aid are far from being fully characterized. The present study is the first to examine the effects of bupropion on visuospatial task-related parietal EEG alpha power asymmetry-an asymmetry that has previously been found to be associated with severity of depressive symptoms (i.e., the more depressive symptoms, the greater alpha power in the right vs. left parietal area [Henriques & Davidson, 1997; Rabe, Debener, Brocke, & Beauducel, 2005])...
February 2017: Experimental and Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28148472/using-social-listening-data-to-monitor-misuse-and-nonmedical-use-of-bupropion-a-content-analysis
#8
Laurie S Anderson, Heidi G Bell, Michael Gilbert, Julie E Davidson, Christina Winter, Monica J Barratt, Beta Win, Jeffery L Painter, Christopher Menone, Jonathan Sayegh, Nabarun Dasgupta
BACKGROUND: The nonmedical use of pharmaceutical products has become a significant public health concern. Traditionally, the evaluation of nonmedical use has focused on controlled substances with addiction risk. Currently, there is no effective means of evaluating the nonmedical use of noncontrolled antidepressants. OBJECTIVE: Social listening, in the context of public health sometimes called infodemiology or infoveillance, is the process of identifying and assessing what is being said about a company, product, brand, or individual, within forms of electronic interactive media...
1, 2017: JMIR Public Health and Surveillance
https://www.readbyqxmd.com/read/28135844/morbidity-and-mortality-associated-with-medications-used-in-the-treatment-of-depression-an-analysis-of-cases-reported-to-u-s-poison-control-centers-2000-2014
#9
J Craig Nelson, Daniel A Spyker
OBJECTIVE: The authors sought to determine the relative morbidity and mortality associated with drugs used to treat depression and to examine specific clinical effects associated with serious outcomes. METHOD: The National Poison Data System, which receives exposure reports from regional poison centers serving the United States, Puerto Rico, and the District of Columbia, was queried for single drug exposures in individuals 12 years and older during the period 2000-2014...
January 31, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28133510/investigation-of-the-regulatory-effects-of-saccharin-on-cytochrome-p450s-in-male-icr-mice
#10
Jun Hyeon Jo, Sunjoo Kim, Tae Won Jeon, Tae Cheon Jeong, Sangkyu Lee
Saccharin, the first artificial sweetener, was discovered in 1879 that do not have any calories and is approximately 200~700 times sweeter than sugar. Saccharin was the most common domestically produced sweetener in Korea in 2010, and it has been used as an alternative to sugar in many products. The interaction between artificial sweeteners and drugs may affect the drug metabolism in patients with diabetes, cancer, and liver damage, this interaction has not been clarified thus far. Here, we examined the effects of the potential saccharin-drug interaction on the activities of 5 cytochrome P450 (CYPs) in male ICR mice; further, we examined the effects of saccharin (4,000 mg/kg) on the pharmacokinetics of bupropion after pretreatment of mice with saccharin for 7 days and after concomitant administration of bupropion and saccharin...
January 2017: Toxicological Research
https://www.readbyqxmd.com/read/28130024/acute-generalized-erythrodermic-pustular-psoriasis-associated-with-bupropion-naltrexone-contrave-%C3%A2
#11
Priyanka A Singh, Kerry P Cassel, Ronald M Moscati, David Eckersley
BACKGROUND: We report a case of erythrodermic pustular psoriasis associated with initiation of bupropion/naltrexone (Contrave®; Orexigen Therapeutics, La Jolla, CA) in a patient with no history of psoriasis. CASE REPORT: A 55-year-old woman was transferred to our tertiary medical center from a community hospital for possible Stevens-Johnson syndrome 3 weeks after initiation of bupropion/naltrexone. The patient was admitted to the burn unit for wound treatment and hydration...
January 24, 2017: Journal of Emergency Medicine
https://www.readbyqxmd.com/read/28129308/comparison-of-the-efficacy-and-safety-of-aripiprazole-versus-bupropion-augmentation-in-patients-with-major-depressive-disorder-unresponsive-to-selective-serotonin-reuptake-inhibitors-a-randomized-prospective-open-label-study
#12
Eun-Jin Cheon, Kwang-Hun Lee, Young-Woo Park, Jong-Hun Lee, Bon-Hoon Koo, Seung-Jae Lee, Hyung-Mo Sung
PURPOSE: The purpose of this study was to compare the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder (MDD) unresponsive to selective serotonin reuptake inhibitors (SSRIs). METHODS: This is the first randomized, prospective, open-label, direct comparison study between aripiprazole and bupropion augmentation. Participants had at least moderately severe depressive symptoms after 4 weeks or more of SSRI treatment...
January 26, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28118671/mechanistic-approach-for-toxic-effects-of-bupropion-in-primary-rat-hepatocytes
#13
Elham Ahmadian, Hossein Babaei, Alireza Mohajjel Nayebi, Aziz Eftekhari, Mohammad Ali Eghbal
Bupropion is a widely prescribed antidepressant/smoke cessation drug. However, hepatotoxicity is one of its side effects reported in some recipients. The mechanisms by which bupropion induces hepatotoxicity is not clear yet. This experiment was intended to assess the cytotoxic mechanisms of bupropion toward primary rat hepatocytes. Additionally, the effect of α-tocopherol succinate (ALPHA-TOS) and N-acetyl cysteine (NAC) and mitochondrial permeability transition (MPT) pore sealing agent cyclosporine A (Cs A) on this toxicity was investigated...
January 24, 2017: Drug Research
https://www.readbyqxmd.com/read/28093398/efficacy-and-safety-of-smoking-cessation-interventions-in-patients-with-cardiovascular-disease-a-network-meta-analysis-of-randomized-controlled-trials
#14
Karine Suissa, Jordan Larivière, Mark J Eisenberg, Maria Eberg, Genevieve C Gore, Roland Grad, Lawrence Joseph, Pauline M Reynier, Kristian B Filion
BACKGROUND: Although the efficacy and safety of smoking cessation interventions are well established, their efficacy and safety in patients with cardiovascular disease (CVD) remain unclear. The objective of this study was to evaluate the efficacy and safety of pharmacological and behavioral smoking cessation interventions in CVD patients via a meta-analysis of randomized controlled trials. METHODS AND RESULTS: EMBASE, PsycINFO, MEDLINE, PubMed, and the Cochrane Tobacco Addiction Specialized Register were searched for randomized controlled trials evaluating the efficacy of smoking cessation pharmacotherapies and behavioral therapies in CVD patients...
January 2017: Circulation. Cardiovascular Quality and Outcomes
https://www.readbyqxmd.com/read/28075103/extended-release-bupropion-for-preventing-seasonal-affective-disorder-in-adults
#15
Megan K Magovern, Amy Crawford-Faucher
No abstract text is available yet for this article.
January 1, 2017: American Family Physician
https://www.readbyqxmd.com/read/28074989/-antidepressants-agents-in-breast-cancer-patients-using-tamoxifen-review-of-basic-and-clinical-evidence
#16
María Elisa Irarrázaval O, Leonardo Gaete G
Tamoxifen (Tmf), is a standard of care for women with estrogen receptor positive (ER+) breast cancer. Endoxifen is a Tmf metabolite generated by cytochrome P450 2D6 (CYP2D6). Antidepressive agents (AD) are often prescribed to women with breast cancer not only for depression, but also for anxiety and hot flashes. Some AD are substrates or inhibitors of the Tmf metabolic pathway. Therefore there may be interactions when Tmf and AD are prescribed simultaneously. Oncologic protection afforded by Tmf may become less effective or null when AD are indicated, especially in poor metabolizing patients...
October 2016: Revista Médica de Chile
https://www.readbyqxmd.com/read/28073796/comparative-efficacy-and-tolerability-of-pharmacological-interventions-for-attention-deficit-hyperactivity-disorder-in-children-adolescents-and-adults-protocol-for-a-systematic-review-and-network-meta-analysis
#17
Samuele Cortese, Nicoletta Adamo, Christina Mohr-Jensen, Adrian J Hayes, Sahar Bhatti, Sara Carucci, Cinzia Del Giovane, Lauren Z Atkinson, Tobias Banaschewski, Emily Simonoff, Alessandro Zuddas, Corrado Barbui, Marianna Purgato, Hans-Christoph Steinhausen, Farhad Shokraneh, Jun Xia, Andrea Cipriani, David Coghill
INTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is a major public health issue. Pharmacological treatments play an important role in the multimodal treatment of ADHD. Currently, there is a lack of up-to-date and comprehensive evidence on how available ADHD drugs compare and rank in terms of efficacy and tolerability, in children or adolescents as well as in adults. We will conduct a network meta-analysis (NMA), integrating direct and indirect comparisons from randomised controlled trials (RCTs), to rank pharmacological treatments for ADHD according to their efficacy and tolerability profiles...
January 10, 2017: BMJ Open
https://www.readbyqxmd.com/read/28064115/do-social-functioning-and-symptoms-improve-with-continuation-antidepressant-treatment-of-persistent-depressive-disorder-an-observational-study
#18
David J Hellerstein, Kallio Hunnicutt-Ferguson, Jonathan W Stewart, Patrick J McGrath, Samantha Keller, Bradley S Peterson, Ying Chen
OBJECTIVE: To determine efficacy of continued treatment with the serotonin norepinephrine reuptake inhibitor duloxetine on symptom reduction and functional improvement in outpatients with dysthymia. METHOD: Fifty outpatients with DSM-IV-TR diagnosed dysthymia who had participated in a 10 week double-blind, placebo-controlled study of duloxetine received open treatment for three months. Nineteen duloxetine responders continued duloxetine, 24 patients initially treated with placebo started open duloxetine treatment, and 7 duloxetine non-responders were treated with desvenlafaxine or bupropion, selected by clinician choice...
December 20, 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28052289/the-pharmacokinetic-interaction-study-between-carvedilol-and-bupropion-in-rats
#19
Maria Bianca Abrudan, Dana Maria Muntean, Ana Maria Gheldiu, Maria Adriana Neag, Laurian Vlase
BACKGROUND/AIMS: The effects of multiple-dose bupropion on the pharmacokinetics of single-dose carvedilol were investigated in order to evaluate this possible drug-drug interaction. METHODS: A preclinical study was conducted among white male Wistar rats. Each rat was cannulated on the femoral vein prior to being connected to BASi Culex ABC®. During the reference period, each rat received an intravenous and an oral dose of 3.57 mg/kg body weight (b.w.) carvedilol, at 2 days distance...
January 5, 2017: Pharmacology
https://www.readbyqxmd.com/read/28040194/nationwide-reconnaissance-of-contaminants-of-emerging-concern-in-source-and-treated-drinking-waters-of-the-united-states-pharmaceuticals
#20
Edward T Furlong, Angela L Batt, Susan T Glassmeyer, Mary C Noriega, Dana W Kolpin, Heath Mash, Kathleen M Schenck
Mobile and persistent chemicals that are present in urban wastewater, such as pharmaceuticals, may survive on-site or municipal wastewater treatment and post-discharge environmental processes. These pharmaceuticals have the potential to reach surface and groundwaters, essential drinking-water sources. A joint, two-phase U.S. Geological Survey-U.S. Environmental Protection Agency study examined source and treated waters from 25 drinking-water treatment plants from across the United States. Treatment plants that had probable wastewater inputs to their source waters were selected to assess the prevalence of pharmaceuticals in such source waters, and to identify which pharmaceuticals persist through drinking-water treatment...
February 1, 2017: Science of the Total Environment
keyword
keyword
11519
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"